Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last181 to 200 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Anesthesia Control Tower Monitoring vs Standard of Care Arm: Measured Anesthetic Concentration | 30,087 of 30,460 29,851 of 30,175 | -0.2 points -0.3 to 0.0 | 60,635 | NCT03923699 Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety |
| Cases vs Controls: Number of Participants BMI ≥30 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person | 685 of 23,725 760 of 36,835 | 0.8 points 0.6 to 1.1 | 60,560 | NCT04969653 The Incidence of Venous Thromboembolism in Atopic Dermatitis |
| People With Ulcerative Colitis (Cases) vs People Without Ulcerative Colitis (Controls): Number of People With Depressive Disorder in People With and Without Ulcerative Colitis | 1,627 of 11,454 5,676 of 45,816 | 1.8 points 1.1 to 2.5 | 57,270 | NCT03836612 Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease |
| People With Ulcerative Colitis (Cases) vs People Without Ulcerative Colitis (Controls): Prevalence of Depressive Episodes (Ulcerative Colitis) | 507 of 11,454 1,666 of 45,816 | 0.8 points 0.4 to 1.2 | 57,270 | NCT03836612 Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease |
| People With Ulcerative Colitis (Cases) vs People Without Ulcerative Colitis (Controls): Prevalence of Anxiety Episodes (Ulcerative Colitis) | 341 of 11,454 1,221 of 45,816 | 0.3 points -0.0 to 0.7 | 57,270 | NCT03836612 Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease |
| Anesthesia Control Tower Monitoring vs Standard of Care Arm: Fresh Gas Flow Rates | 19,839 of 26,837 19,899 of 26,739 | -0.5 points -1.2 to 0.2 | 53,576 | NCT03923699 Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety |
| LDCT Screening vs CXR Screening: Lung Cancer Diagnoses | 1,060 of 26,722 941 of 26,732 | 0.4 points 0.1 to 0.8 | 53,454 | NCT00047385 National Lung Screening Trial (NLST) Screening |
| LDCT Screening vs CXR Screening: Deaths From All Causes in All Randomized Participants. | 1,877 of 26,722 2,000 of 26,732 | -0.5 points -0.9 to -0.0 | 53,454 | NCT00047385 National Lung Screening Trial (NLST) Screening |
| LDCT Screening vs CXR Screening: Lung Cancer Deaths | 356 of 26,722 443 of 26,732 | -0.3 points -0.5 to -0.1 | 53,454 | NCT00047385 National Lung Screening Trial (NLST) Screening |
| Low-Dose CT vs Chest X-ray: serious adverse events | 0 of 26,722 2 of 26,732 | -0.0 points -0.0 to 0.0 | 53,454 | NCT00047385 National Lung Screening Trial (NLST) Screening |
| Type 1 Diabetes vs Type 2 Diabetes: serious adverse events | 130 of 13,529 80 of 37,641 | 0.7 points 0.6 to 0.9 | 51,170 | NCT00659295 Observational Study to Evaluate the Safety of Levemir® in Diabetes |
| Oxygen Use Cohort vs No Oxygen Use Cohort: Number of Participants With Disease Progression From Pre-index Forced Vital Capacity (FVC) Result to Index Date | 162 of 24,680 110 of 24,680 | 0.2 points 0.1 to 0.3 | 49,360 | NCT05957198 Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease |
| Oxygen Use Cohort vs No Oxygen Use Cohort: Number of Participants With Disease Progression From Index Date to Follow-up Forced Vital Capacity (FVC) Result | 575 of 24,680 456 of 24,680 | 0.5 points 0.2 to 0.7 | 49,360 | NCT05957198 Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease |
| Intervention Arm vs Control Arm: Percentage of Patients With Well-controlled Blood Pressure | 16,910 of 24,747 16,441 of 24,463 | 1.1 points 0.3 to 1.9 | 49,210 | NCT05030467 Leveraging Electronic Health Record (EHR) Tools to Reduce Health Disparities for Patients With Uncontrolled Hypertension |
| Intervention vs Control: deaths from any cause | 493 of 23,546 483 of 23,787 | 0.1 points -0.2 to 0.3 | 47,333 | NCT03259373 IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation |
| Intervention vs Control: serious adverse events | 737 of 23,546 760 of 23,787 | -0.1 points -0.4 to 0.3 | 47,333 | NCT03259373 IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation |
| Caring Contact Letters vs Caring Contact Control: serious adverse events | 1,177 of 22,380 1,071 of 22,775 | 0.6 points 0.2 to 1.0 | 45,155 | NCT05579600 Suicide Prevention for Criminal Legal Involved Managed Care Subscribers |
| Text-Messaging (TM) vs Text-Messaging Plus Patient Navigation (TM+PN): Reach-TM Engage | 2,594 of 22,145 2,401 of 22,584 | 1.1 points 0.5 to 1.7 | 44,729 | NCT04939532 SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Testing Among Utah Community Health Centers |
| Cases vs Controls: Number of Participants Having History of an Allergic Condition With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person | 193 of 18,742 203 of 25,088 | 0.2 points 0.0 to 0.4 | 43,830 | NCT04969653 The Incidence of Venous Thromboembolism in Atopic Dermatitis |
| Double-blind Phase: Ad26.COV2.S 5*10^10 vp vs Double-blind Phase: Placebo: Number of Participants With First Occurrence of Molecularly Confirmed, Moderate to Severe/Critical COVID-19 for Seronegative Participants (Double Blind Phase) | 575 of 21,898 1,189 of 21,890 | -2.8 points -3.2 to -2.4 | 43,788 | NCT04505722 A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=10
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03923699-fd2d7938",
"title": "Anesthesia Control Tower Monitoring vs Standard of Care Arm: Measured Anesthetic Concentration",
"summary": "30087 of 30460 against 29851 of 30175; risk difference -0.2 points, 95% interval -0.3 to 0.0; NCT03923699, Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety",
"record": "/library/comparisons/NCT03923699-fd2d7938",
"nct_id": "NCT03923699",
"kind": "outcome",
"participants": 60635,
"risk_difference": {
"value": -0.0015082025892950712,
"lower": -0.00321105785179691,
"upper": 0.00019049754577488403
},
"group_1": "30,087 of 30,460",
"group_2": "29,851 of 30,175",
"difference": "-0.2 points",
"interval": "-0.3 to 0.0",
"trial_title": "Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety"
},
{
"id": "NCT04969653-2edb4875",
"title": "Cases vs Controls: Number of Participants BMI ≥30 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person",
"summary": "685 of 23725 against 760 of 36835; risk difference 0.8 points, 95% interval 0.6 to 1.1; NCT04969653, The Incidence of Venous Thromboembolism in Atopic Dermatitis",
"record": "/library/comparisons/NCT04969653-2edb4875",
"nct_id": "NCT04969653",
"kind": "outcome",
"participants": 60560,
"risk_difference": {
"value": 0.008239946802325124,
"lower": 0.005693780462501227,
"upper": 0.010855851184297296
},
"group_1": "685 of 23,725",
"group_2": "760 of 36,835",
"difference": "0.8 points",
"interval": "0.6 to 1.1",
"trial_title": "The Incidence of Venous Thromboembolism in Atopic Dermatitis"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=11",
"request_id": "suqXsHXO1uWQLlCn"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant